Status:
COMPLETED
A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine
Lead Sponsor:
PowderMed
Conditions:
Influenza
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the abi...
Detailed Description
Influenza is a contagious disease of the upper airways and the lungs. It rapidly spreads around the world in seasonal epidemics, killing hundreds of thousands of people and having high economic conseq...
Eligibility Criteria
Inclusion
- Ages Eligible for Study:
- 18 Years - 50 Years
- Genders Eligible for Study: Both
- Accepts Healthy Volunteers
- Criteria
- Healthy adult volunteers (women must be of non child-bearing potential)
- Provided written informed consent
Exclusion
- No significant concomitant illness
- No allergy to gold
- No immunosuppression due to disease or treatment
- No previous flu vaccination in 2005 or 2006
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
189 Patients enrolled
Trial Details
Trial ID
NCT00375206
Start Date
September 1 2006
End Date
January 1 2007
Last Update
January 29 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Quintiles Lenexa (QLX)
Lenexa, Kansas, United States, 66219
2
Biokinetic
Springfield, Missouri, United States, 65802